시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 성인 T세포 백혈병/림프종 치료 시장 보고서(2025년)
Adult T-Cell Leukemia/Lymphoma Treatment Global Market Report 2025
상품코드 : 1720699
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

성인 T세포 백혈병/림프종 치료 시장 규모는 향후 몇 년간 강력한 성장이 전망될 예정입니다. 예측 기간의 성장은 면역요법의 채용, 개발도상지역에 있어서의 헬스케어 인프라의 개선 등에 기인한다고 생각됩니다. 주요 동향으로서는 면역요법의 이용 확대, 시장에 있어서 임상 검사의 확대, 약제 개발에 있어서 인공지능의 통합, 병용 요법의 중시, 독성이 낮은 치료법의 개발 등을 들 수 있습니다.

임상 검사 증가는 성인 T세포 백혈병/림프종 치료 시장의 확대를 촉진할 것으로 예측됩니다. 이 임상 검사는 새로운 치료법의 검사, 기존의 치료 프로토콜의 최적화, 혁신적인 약제의 평가 등, 성인 T세포 백혈병/림프종 치료의 진보에 중요한 역할을 하고 있습니다. 궁극적으로는 환자의 결과를 개선하고 이 희귀하고 과제도 많은 질병에 대한 이용 가능한 치료 옵션을 확대하게 됩니다. 예를 들어, 2024년 2월 미국 정부 웹 리소스인 ClinicalTrials.gov는 임상시험 결과를 발표하는 건수가 2022년 4,024건에서 2023년 5,063건으로 증가했다고 보고했습니다. 그 결과, 임상검사수 증가가 성인 T세포 백혈병/림프종 치료시장의 성장에 기여하고 있습니다.

이 시장 주요 기업은 생존율과 치료 효과를 높이기 위해 혁신적인 약제 억제제의 개발에 주력하고 있습니다. 예를 들어, 2022년 12월 일본에 본사를 둔 제약 회사인 다이이찌 산쿄 컴퍼니 리미티드는 성인 T세포 백혈병/림프종 치료제로 이지하미아를 출시했습니다. 이 선진적인 표적 치료는 성인 T세포 백혈병/림프종의 암세포의 개발과 진행에 중요한 역할을 하는 EZH1과 EZH2 효소를 억제합니다. 이를 통해 EZHARMIA는 건강한 세포에 대한 손상을 최소화하고, 특히 재발 또는 난치성 환자에 대한 전통적인 화학 요법을 대체하는 보다 정밀한 치료 접근법을 설명합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

Adult T-cell leukemia or lymphoma treatment refers to the medical management of a rare and aggressive cancer caused by the HTLV-1 virus, which affects T-lymphocytes. The primary goal is to control disease progression, relieve symptoms, and enhance the patient's quality of life. The treatment approach varies based on the subtype and severity of the condition.

The primary treatment options for adult T-cell leukemia or lymphoma include chemotherapy, targeted therapies, immunotherapies, combination therapies, and stem cell transplantation. Chemotherapy utilizes potent drugs to eliminate rapidly dividing cancer cells throughout the body. The disease subtypes include acute adult T-cell leukemia or lymphoma, lymphomatous adult T-cell leukemia or lymphoma, chronic adult T-cell leukemia or lymphoma, and smoldering adult T-cell leukemia or lymphoma. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. The end users comprise hospitals and clinics, specialty cancer centers, and research institutes.

The adult T-cell leukemia or lymphoma treatment market research report is one of a series of new reports from The Business Research Company that provides adult T-cell leukemia or lymphoma treatment market statistics, including adult T-cell leukemia or lymphoma treatment industry global market size, regional shares, competitors with an adult T-cell leukemia or lymphoma treatment market share, detailed adult T-cell leukemia or lymphoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the adult T-cell leukemia or lymphoma treatment industry. This adult T-cell leukemia or lymphoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adult T-cell leukemia or lymphoma treatment market size has grown strongly in recent years. It will grow from $1.83 billion in 2024 to $2.00 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to the rising prevalence of the HTLV-1 virus, improved diagnostic accuracy, advancements in and widespread adoption of chemotherapy regimens, global awareness initiatives, and the increasing incidence of lymphoma cancer.

The adult T-cell leukemia or lymphoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.79 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to the approval of new therapeutic agents, a rising incidence in non-endemic regions, a focus on combination therapies, increased government funding for rare diseases, the adoption of immunotherapies, and improvements in healthcare infrastructure in developing regions. Major trends include the increased use of immunotherapies, expansion of clinical trials in emerging markets, integration of artificial intelligence in drug development, emphasis on combination therapies, and the development of less toxic treatment options.

The growing number of clinical trials is expected to drive the expansion of the adult T-cell leukemia or lymphoma treatment market. Clinical trials are research studies conducted to assess the safety, efficacy, and potential side effects of medical treatments, drugs, or devices in humans, with the goal of improving healthcare outcomes. These trials play a crucial role in advancing adult T-cell leukemia or lymphoma treatment by testing new therapies, optimizing existing treatment protocols, and evaluating innovative drugs, ultimately improving patient outcomes and expanding available treatment options for this rare and challenging condition. For example, in February 2024, ClinicalTrials.gov, a US-based government web resource, reported that the number of clinical trials publishing findings increased from 4,024 in 2022 to 5,063 in 2023. As a result, the rising number of clinical trials is contributing to the growth of the adult T-cell leukemia or lymphoma treatment market.

Leading companies in the market are focusing on the development of innovative drug inhibitors to enhance survival rates and treatment effectiveness. Drug inhibitors are compounds designed to block specific biological targets, such as enzymes or receptors, to treat diseases by modulating their underlying molecular mechanisms. For instance, in December 2022, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, introduced EZHARMIA for the treatment of adult T-cell leukemia or lymphoma. This advanced targeted therapy inhibits EZH1 and EZH2 enzymes, which play a critical role in the development and progression of cancer cells in adult T-cell leukemia-lymphoma (ATLL). By specifically targeting these enzymes, EZHARMIA offers a more precise treatment approach that minimizes damage to healthy cells, providing an alternative to traditional chemotherapy, particularly for patients with relapsed or refractory cases of the disease.

In December 2023, Pfizer Inc., a US-based biopharmaceutical company, acquired Seagen for $43 billion. This acquisition aims to strengthen Pfizer's cancer treatment capabilities by leveraging Seagen's expertise in antibody-drug conjugate (ADC) technology, which enables targeted tumor cell destruction while minimizing harm to healthy tissues. Seagen Inc., a US-based biotechnology company, specializes in the discovery, development, and commercialization of groundbreaking cancer therapies, including drugs such as brentuximab vedotin.

Major players in the adult T-cell leukemia or lymphoma treatment market are Pfizer Inc., Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Kyowa Kirin Co. Ltd., HUYA Bioscience International, BioCryst Pharmaceuticals, Innate Pharma SA, Legend Biotech Corporation, Bluebird Bio Inc., Acrotech Biopharma Inc., Erytech Pharma Inc., Armata Pharmaceuticals Inc., Autolus Therapeutics plc, Celyad Oncology SA, miRagen Therapeutics Inc.

North America was the largest region in the adult T-cell leukemia or lymphoma treatment market in 2024. The regions covered in adult T-cell leukemia or lymphoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adult T-cell leukemia or lymphoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adult T-cell leukemia or lymphoma treatment market consists of revenues earned by entities that provide services such as antiviral therapy, radiotherapy, CAR-T cell therapy, and hematopoietic stem cell transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The adult T-cell leukemia or lymphoma treatment market also includes sales of immune checkpoint inhibitors and epigenetic modulators. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adult T-Cell Leukemia/Lymphoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adult t-cell leukemia/lymphoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for adult t-cell leukemia/lymphoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adult t-cell leukemia/lymphoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Adult T-Cell Leukemia Or Lymphoma Treatment Market Characteristics

3. Adult T-Cell Leukemia Or Lymphoma Treatment Market Trends And Strategies

4. Adult T-Cell Leukemia Or Lymphoma Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Adult T-Cell Leukemia Or Lymphoma Treatment Growth Analysis And Strategic Analysis Framework

6. Adult T-Cell Leukemia Or Lymphoma Treatment Market Segmentation

7. Adult T-Cell Leukemia Or Lymphoma Treatment Market Regional And Country Analysis

8. Asia-Pacific Adult T-Cell Leukemia Or Lymphoma Treatment Market

9. China Adult T-Cell Leukemia Or Lymphoma Treatment Market

10. India Adult T-Cell Leukemia Or Lymphoma Treatment Market

11. Japan Adult T-Cell Leukemia Or Lymphoma Treatment Market

12. Australia Adult T-Cell Leukemia Or Lymphoma Treatment Market

13. Indonesia Adult T-Cell Leukemia Or Lymphoma Treatment Market

14. South Korea Adult T-Cell Leukemia Or Lymphoma Treatment Market

15. Western Europe Adult T-Cell Leukemia Or Lymphoma Treatment Market

16. UK Adult T-Cell Leukemia Or Lymphoma Treatment Market

17. Germany Adult T-Cell Leukemia Or Lymphoma Treatment Market

18. France Adult T-Cell Leukemia Or Lymphoma Treatment Market

19. Italy Adult T-Cell Leukemia Or Lymphoma Treatment Market

20. Spain Adult T-Cell Leukemia Or Lymphoma Treatment Market

21. Eastern Europe Adult T-Cell Leukemia Or Lymphoma Treatment Market

22. Russia Adult T-Cell Leukemia Or Lymphoma Treatment Market

23. North America Adult T-Cell Leukemia Or Lymphoma Treatment Market

24. USA Adult T-Cell Leukemia Or Lymphoma Treatment Market

25. Canada Adult T-Cell Leukemia Or Lymphoma Treatment Market

26. South America Adult T-Cell Leukemia Or Lymphoma Treatment Market

27. Brazil Adult T-Cell Leukemia Or Lymphoma Treatment Market

28. Middle East Adult T-Cell Leukemia Or Lymphoma Treatment Market

29. Africa Adult T-Cell Leukemia Or Lymphoma Treatment Market

30. Adult T-Cell Leukemia Or Lymphoma Treatment Market Competitive Landscape And Company Profiles

31. Adult T-Cell Leukemia Or Lymphoma Treatment Market Other Major And Innovative Companies

32. Global Adult T-Cell Leukemia Or Lymphoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adult T-Cell Leukemia Or Lymphoma Treatment Market

34. Recent Developments In The Adult T-Cell Leukemia Or Lymphoma Treatment Market

35. Adult T-Cell Leukemia Or Lymphoma Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기